T. Rowe Price Associates’s BioLife Solutions BLFS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $769K | Buy |
40,295
+10,512
| +35% | +$232K | ﹤0.01% | 2265 |
|
|
2025
Q4 | $721K | Buy |
29,783
+4,014
| +16% | +$105K | ﹤0.01% | 2230 |
|
|
2025
Q3 | $658K | Buy |
25,769
+1,712
| +7% | +$40.6K | ﹤0.01% | 2261 |
|
|
2025
Q2 | $519K | Buy |
24,057
+3,133
| +15% | +$70.6K | ﹤0.01% | 2280 |
|
|
2025
Q1 | $478K | Buy |
20,924
+1,485
| +8% | +$39.1K | ﹤0.01% | 2262 |
|
|
2024
Q4 | $505K | Buy |
19,439
+2,628
| +16% | +$65.4K | ﹤0.01% | 2275 |
|
|
2024
Q3 | $421K | Buy |
16,811
+404
| +2% | +$9.54K | ﹤0.01% | 2329 |
|
|
2024
Q2 | $352K | Buy |
16,407
+1,278
| +8% | +$24.8K | ﹤0.01% | 2344 |
|
|
2024
Q1 | $281K | Buy |
15,129
+1,374
| +10% | +$24K | ﹤0.01% | 2464 |
|
|
2023
Q4 | $224K | Buy |
13,755
+858
| +7% | +$10.9K | ﹤0.01% | 2494 |
|
|
2023
Q3 | $179K | Buy |
12,897
+692
| +6% | +$10.9K | ﹤0.01% | 2539 |
|
|
2023
Q2 | $270K | Buy |
12,205
+768
| +7% | +$16.2K | ﹤0.01% | 2413 |
|
|
2023
Q1 | $249K | Buy |
11,437
+571
| +5% | +$12.8K | ﹤0.01% | 2430 |
|
|
2022
Q4 | $198K | Sell |
10,866
-3,695
| -25% | -$76.3K | ﹤0.01% | 2535 |
|
|
2022
Q3 | $332K | Buy |
14,561
+944
| +7% | +$20.2K | ﹤0.01% | 2333 |
|
|
2022
Q2 | $188K | Buy |
+13,617
| New | +$200K | ﹤0.01% | 2619 |
|
|
2022
Q1 | – | Sell |
-5,962
| Closed | -$222K | – | 2983 |
|
|
2021
Q4 | $222K | Buy |
+5,962
| New | +$256K | ﹤0.01% | 2714 |
|
|
2020
Q1 | – | Sell |
-29,957
| Closed | -$485K | – | 2519 |
|
|
2019
Q4 | $485K | Buy |
29,957
+300
| +1% | +$4.88K | ﹤0.01% | 2158 |
|
|
2019
Q3 | $493K | Buy |
29,657
+31
| +0.1% | +$582 | ﹤0.01% | 2108 |
|
|
2019
Q2 | $502K | Buy |
29,626
+7,226
| +32% | +$126K | ﹤0.01% | 2109 |
|
|
2019
Q1 | $401K | Buy |
22,400
+7,500
| +50% | +$119K | ﹤0.01% | 2196 |
|
|
2018
Q4 | $179K | Hold |
14,900
| – | – | ﹤0.01% | 2430 |
|
|
2018
Q3 | $261K | Sell |
14,900
-13,300
| -47% | -$263K | ﹤0.01% | 2402 |
|
|
2018
Q2 | $322K | Hold |
28,200
| – | – | ﹤0.01% | 2326 |
|
|
2018
Q1 | $144K | Buy |
28,200
+3,400
| +14% | +$18.4K | ﹤0.01% | 2458 |
|
|
2017
Q4 | $149K | Buy |
24,800
+7,900
| +47% | +$45.5K | ﹤0.01% | 2469 |
|
|
2017
Q3 | $97K | Hold |
16,900
| – | – | ﹤0.01% | 2499 |
|
|
2017
Q2 | $40K | Buy |
16,900
+1,400
| +9% | +$3.05K | ﹤0.01% | 2539 |
|
|
2017
Q1 | $32K | Buy |
15,500
+3,700
| +31% | +$7.17K | ﹤0.01% | 2556 |
|
|
2016
Q4 | $19K | Hold |
11,800
| – | – | ﹤0.01% | 2543 |
|
|
2016
Q3 | $22K | Buy |
+11,800
| New | +$22.4K | ﹤0.01% | 2518 |
|
Other funds holding BLFS
CC
VCM
FAM
T. Rowe Price Associates's BLFS Position: Q1 2026 in Review
T. Rowe Price Associates increased its BioLife Solutions (BLFS) stake by 35% in Q1 2026, buying an estimated $232K and bringing the position to 40,295 shares worth $769K. The position accounts for ﹤0.01% of the portfolio, ranked #2265.
T. Rowe Price Associates first reported a position in BLFS in Q3 2016 and has held it in 31 quarters since. 187 funds tracked by Wall St. Rank hold BLFS as of Q1 2026.
- T. Rowe Price Associates held 40,295 shares of BioLife Solutions worth $769K as of Q1 2026.
- T. Rowe Price Associates bought 10,512 BioLife Solutions shares in Q1 2026, an estimated $232K.
- BioLife Solutions made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2265 holding.
- T. Rowe Price Associates first reported a position in BioLife Solutions in Q3 2016 and has held it in 31 quarters since.
- 187 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.